أعرض في EDS

The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience

التفاصيل البيبلوغرافية
العنوان: The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience
المؤلفون: Qingchun Zeng, Bin-Tao Huang, Bing-Sheng Li, Wei-Hong Zhao, Arati Gurung, Zhen Xiao
المصدر: Medical oncology (Northwood, London, England). 29(3)
سنة النشر: 2011
مصطلحات موضوعية: Acute promyelocytic leukemia, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Adolescent, Antineoplastic Agents, Tretinoin, Kaplan-Meier Estimate, Arsenicals, Disease-Free Survival, chemistry.chemical_compound, Young Adult, Arsenic Trioxide, Leukemia, Promyelocytic, Acute, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, Arsenic trioxide, Aged, Hematology, Adult patients, business.industry, Daunorubicin, Cytarabine, Consolidation Chemotherapy, Oxides, General Medicine, Middle Aged, medicine.disease, Surgery, Regimen, Leukemia, chemistry, Cohort, Female, business
الوصف: The purpose of the study was to evaluate event-free survival (EFS), overall survival (OS) and safety for early addition of arsenic trioxide (As(2)O(3)) as frontline consolidation therapy compared to high-dose arabinoside (HiDAC) in adult patients with de novo acute promyelocytic leukemia (APL). 271 patients (aged 17-65 years) received consolidation therapy containing As(2)O(3) (two 21-day courses) or HiDAC regimen. EFS at 5 years was 75% versus 54% (P0.001), and OS at 5 years was 83% versus 71% (P = 0.002) in As(2)O(3) and HiDAC treatment arms. 139 patients treated with As(2)O(3), EFS at 5 years reached 79% versus 56% (P = 0.014), but OS at 5 years was 77% versus 84% (P = 0.32) in low-risk (WBC ≤ 10 × 10(9)/L) and high-risk (WBC10 × 10(9)/L) cohorts. Further, patients treated with As(2)O(3) rarely incurred agranulocytosis (1.4%, P0.001), or severe infection (0.7%, P0.001). It is still very well tolerated compared to HiDAC. We confirmed that As(2)O(3) as a first-line consolidation regimen provided significant benefits of OS to patients with APL. The As(2)O(3) regimen made low-risk patients gain more EFS benefits than high-risk group. The high-risk cohort receiving As(2)O(3) overcame the negative impact, yielding OS similar to that for with the low-risk patients treated with As(2)O(3).
تدمد: 1559-131X
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae12d6762b568e3975fc4f58ab527db1
https://pubmed.ncbi.nlm.nih.gov/22038728
Rights: CLOSED
رقم الانضمام: edsair.doi.dedup.....ae12d6762b568e3975fc4f58ab527db1
قاعدة البيانات: OpenAIRE
ResultId 1
Header edsair
OpenAIRE
edsair.doi.dedup.....ae12d6762b568e3975fc4f58ab527db1
770
3

unknown
769.77587890625
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ae12d6762b568e3975fc4f58ab527db1&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae12d6762b568e3975fc4f58ab527db1# [Name] => EDS - OpenAIRE [Category] => fullText [Text] => View record in OpenAIRE [MouseOverText] => View record in OpenAIRE ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Qingchun+Zeng%22">Qingchun Zeng</searchLink><br /><searchLink fieldCode="AR" term="%22Bin-Tao+Huang%22">Bin-Tao Huang</searchLink><br /><searchLink fieldCode="AR" term="%22Bing-Sheng+Li%22">Bing-Sheng Li</searchLink><br /><searchLink fieldCode="AR" term="%22Wei-Hong+Zhao%22">Wei-Hong Zhao</searchLink><br /><searchLink fieldCode="AR" term="%22Arati+Gurung%22">Arati Gurung</searchLink><br /><searchLink fieldCode="AR" term="%22Zhen+Xiao%22">Zhen Xiao</searchLink> )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>Medical oncology (Northwood, London, England)</i>. 29(3) )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2011 )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Acute+promyelocytic+leukemia%22">Acute promyelocytic leukemia</searchLink><br /><searchLink fieldCode="DE" term="%22Oncology%22">Oncology</searchLink><br /><searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22Cancer+Research%22">Cancer Research</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22Adolescent%22">Adolescent</searchLink><br /><searchLink fieldCode="DE" term="%22Antineoplastic+Agents%22">Antineoplastic Agents</searchLink><br /><searchLink fieldCode="DE" term="%22Tretinoin%22">Tretinoin</searchLink><br /><searchLink fieldCode="DE" term="%22Kaplan-Meier+Estimate%22">Kaplan-Meier Estimate</searchLink><br /><searchLink fieldCode="DE" term="%22Arsenicals%22">Arsenicals</searchLink><br /><searchLink fieldCode="DE" term="%22Disease-Free+Survival%22">Disease-Free Survival</searchLink><br /><searchLink fieldCode="DE" term="%22chemistry%2Echemical%5Fcompound%22">chemistry.chemical_compound</searchLink><br /><searchLink fieldCode="DE" term="%22Young+Adult%22">Young Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Arsenic+Trioxide%22">Arsenic Trioxide</searchLink><br /><searchLink fieldCode="DE" term="%22Leukemia%2C+Promyelocytic%2C+Acute%22">Leukemia, Promyelocytic, Acute</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Antineoplastic+Combined+Chemotherapy+Protocols%22">Antineoplastic Combined Chemotherapy Protocols</searchLink><br /><searchLink fieldCode="DE" term="%22Medicine%22">Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Arsenic+trioxide%22">Arsenic trioxide</searchLink><br /><searchLink fieldCode="DE" term="%22Aged%22">Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Hematology%22">Hematology</searchLink><br /><searchLink fieldCode="DE" term="%22Adult+patients%22">Adult patients</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Daunorubicin%22">Daunorubicin</searchLink><br /><searchLink fieldCode="DE" term="%22Cytarabine%22">Cytarabine</searchLink><br /><searchLink fieldCode="DE" term="%22Consolidation+Chemotherapy%22">Consolidation Chemotherapy</searchLink><br /><searchLink fieldCode="DE" term="%22Oxides%22">Oxides</searchLink><br /><searchLink fieldCode="DE" term="%22General+Medicine%22">General Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22Surgery%22">Surgery</searchLink><br /><searchLink fieldCode="DE" term="%22Regimen%22">Regimen</searchLink><br /><searchLink fieldCode="DE" term="%22Leukemia%22">Leukemia</searchLink><br /><searchLink fieldCode="DE" term="%22chemistry%22">chemistry</searchLink><br /><searchLink fieldCode="DE" term="%22Cohort%22">Cohort</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink> )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => The purpose of the study was to evaluate event-free survival (EFS), overall survival (OS) and safety for early addition of arsenic trioxide (As(2)O(3)) as frontline consolidation therapy compared to high-dose arabinoside (HiDAC) in adult patients with de novo acute promyelocytic leukemia (APL). 271 patients (aged 17-65 years) received consolidation therapy containing As(2)O(3) (two 21-day courses) or HiDAC regimen. EFS at 5 years was 75% versus 54% (P0.001), and OS at 5 years was 83% versus 71% (P = 0.002) in As(2)O(3) and HiDAC treatment arms. 139 patients treated with As(2)O(3), EFS at 5 years reached 79% versus 56% (P = 0.014), but OS at 5 years was 77% versus 84% (P = 0.32) in low-risk (WBC ≤ 10 × 10(9)/L) and high-risk (WBC10 × 10(9)/L) cohorts. Further, patients treated with As(2)O(3) rarely incurred agranulocytosis (1.4%, P0.001), or severe infection (0.7%, P0.001). It is still very well tolerated compared to HiDAC. We confirmed that As(2)O(3) as a first-line consolidation regimen provided significant benefits of OS to patients with APL. The As(2)O(3) regimen made low-risk patients gain more EFS benefits than high-risk group. The high-risk cohort receiving As(2)O(3) overcame the negative impact, yielding OS similar to that for with the low-risk patients treated with As(2)O(3). )
Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1559-131X )
Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae12d6762b568e3975fc4f58ab527db1" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae12d6762b568e3975fc4f58ab527db1</link><br /><link linkTarget="URL" linkTerm="https://pubmed.ncbi.nlm.nih.gov/22038728" linkWindow="_blank">https://pubmed.ncbi.nlm.nih.gov/22038728</link> )
Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => CLOSED )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....ae12d6762b568e3975fc4f58ab527db1 )
RecordInfo Array ( [BibEntity] => Array ( [Languages] => Array ( [0] => Array ( [Text] => Undetermined ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => Acute promyelocytic leukemia [Type] => general ) [1] => Array ( [SubjectFull] => Oncology [Type] => general ) [2] => Array ( [SubjectFull] => Adult [Type] => general ) [3] => Array ( [SubjectFull] => Male [Type] => general ) [4] => Array ( [SubjectFull] => Cancer Research [Type] => general ) [5] => Array ( [SubjectFull] => medicine.medical_specialty [Type] => general ) [6] => Array ( [SubjectFull] => Adolescent [Type] => general ) [7] => Array ( [SubjectFull] => Antineoplastic Agents [Type] => general ) [8] => Array ( [SubjectFull] => Tretinoin [Type] => general ) [9] => Array ( [SubjectFull] => Kaplan-Meier Estimate [Type] => general ) [10] => Array ( [SubjectFull] => Arsenicals [Type] => general ) [11] => Array ( [SubjectFull] => Disease-Free Survival [Type] => general ) [12] => Array ( [SubjectFull] => chemistry.chemical_compound [Type] => general ) [13] => Array ( [SubjectFull] => Young Adult [Type] => general ) [14] => Array ( [SubjectFull] => Arsenic Trioxide [Type] => general ) [15] => Array ( [SubjectFull] => Leukemia, Promyelocytic, Acute [Type] => general ) [16] => Array ( [SubjectFull] => Internal medicine [Type] => general ) [17] => Array ( [SubjectFull] => Antineoplastic Combined Chemotherapy Protocols [Type] => general ) [18] => Array ( [SubjectFull] => Medicine [Type] => general ) [19] => Array ( [SubjectFull] => Humans [Type] => general ) [20] => Array ( [SubjectFull] => Arsenic trioxide [Type] => general ) [21] => Array ( [SubjectFull] => Aged [Type] => general ) [22] => Array ( [SubjectFull] => Hematology [Type] => general ) [23] => Array ( [SubjectFull] => Adult patients [Type] => general ) [24] => Array ( [SubjectFull] => business.industry [Type] => general ) [25] => Array ( [SubjectFull] => Daunorubicin [Type] => general ) [26] => Array ( [SubjectFull] => Cytarabine [Type] => general ) [27] => Array ( [SubjectFull] => Consolidation Chemotherapy [Type] => general ) [28] => Array ( [SubjectFull] => Oxides [Type] => general ) [29] => Array ( [SubjectFull] => General Medicine [Type] => general ) [30] => Array ( [SubjectFull] => Middle Aged [Type] => general ) [31] => Array ( [SubjectFull] => medicine.disease [Type] => general ) [32] => Array ( [SubjectFull] => Surgery [Type] => general ) [33] => Array ( [SubjectFull] => Regimen [Type] => general ) [34] => Array ( [SubjectFull] => Leukemia [Type] => general ) [35] => Array ( [SubjectFull] => chemistry [Type] => general ) [36] => Array ( [SubjectFull] => Cohort [Type] => general ) [37] => Array ( [SubjectFull] => Female [Type] => general ) [38] => Array ( [SubjectFull] => business [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => The early addition of arsenic trioxide versus high-dose arabinoside is more effective and safe as consolidation chemotherapy for risk-tailored patients with acute promyelocytic leukemia: multicenter experience [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Qingchun Zeng ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Bin-Tao Huang ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Bing-Sheng Li ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Wei-Hong Zhao ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Arati Gurung ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Zhen Xiao ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 15 [M] => 10 [Type] => published [Y] => 2011 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 1559131X ) [1] => Array ( [Type] => issn-locals [Value] => edsair ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 29 ) [1] => Array ( [Type] => issue [Value] => 3 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Medical oncology (Northwood, London, England) [Type] => main ) ) ) ) ) ) )
IllustrationInfo